Inmunova

Executive Summary

Inmunova is an Argentine biotechnology company focused on developing innovative antibody and recombinant protein-based therapies for infectious diseases and envenomations. Founded in 2009 and headquartered in Buenos Aires, the company has built a robust platform for generating biologics against high-mortality conditions, including COVID-19 and snakebites. Inmunova's lead programs are in Phase 2 clinical development, targeting both viral infections and neglected tropical diseases. The company's strategy leverages its proprietary technology to create affordable, scalable treatments for Latin American and global markets. Despite limited disclosed funding, Inmunova has demonstrated scientific capability and potential for partnerships or licensing deals to advance its pipeline.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 data readout for COVID-19 antibody therapy50% success
• Q4 2026Partnership or licensing agreement for snakebite antivenom program40% success
• Q1 2027Regulatory submission for Phase 2 trial initiation in a new indication60% success